Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
PMID: 23361642
2013
The Journal of antimicrobial chemotherapy
Abstract: The prevalence of K65R and M184I/V was 0.06% (1/1729) and 1% (18/1729), respectively.
Abstract: We also studied the M184V/I and K65R mutations for emtricitabine and tenofovir, respectively.
HIV-1 drug resistance and associated factors among adults failing first-line highly active antiretroviral therapy in Ho Chi Minh City, Vietnam.
Abstract: Among 87 participating individuals with VL >=1,000 copies/mL, 11 people still harbored a wild-type strain, while 76 participants harbored a HIV-1 drug-resistant strain (2 of which were against protease inhibitors); common DRMs were M184I/V (74%), Y181I/C/V (39%), G190A/S (32%), T215Y/F (32%), and K103N (31%).
Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir.
Introduction: At the same time, this switch would obviate the problem of initiating therapy with an rilpivirine-based regimen at high viral loads and presumably avoid the problem of M184I/E138K drug resistance in such populations.
Introduction: In general, rilpivirine-treated patients also had higher rates of virologic failure than efavirenz-treated patients in the Phase III ECHO and THRIVE trials, ie, 10% versus 6%, and Table 2 shows that the most common mutations among the rilpivirine failures were E138K and M184I.
Introduction: Seemingly, the E138K mutation can compensate for the fitness deficits of both M184I and M184V, thus restoring the replicative capacity of viruses containing M184I/V toget
Human APOBEC3G-mediated hypermutation is associated with antiretroviral therapy failure in HIV-1 subtype C-infected individuals.
PMID: 23443042
2013
Journal of the International AIDS Society
Abstract: In therapy-naive individuals, hypermutated proviral DNA with M184I and M230I mutations due to the editing of hA3G, had stop codons in the open reading frames and the same mutations were absent in the plasma virus.
Abstract: It is unlikely that viral variants, which exhibit hypermutated sequences and M184I and/or M230I, will mature and expand in vivo.
Result: As expected, among the NRTI and NNRTI mutations, M184I/V (71.9%), T215Y/F (34.4%), K103N (34.3%), and Y181C (28.1%) were the most prevalent in any of the compartments.
Result: In one patient with hypermutated sequence, PMID: 23444139
2013
Nucleic acids research
Discussion: K65R, L74V, Q151N and M184I) have a relatively minor impact on error distribution, with frameshifts occurring mostly at nucleotide runs.
Restriction fragment mass polymorphism (RFMP) analysis based on MALDI-TOF mass spectrometry for detecting antiretroviral resistance in HIV-1 infected patients.
PMID: 23480551
2013
Clinical microbiology and infection
Abstract: The concordance rates between the RFMP and direct sequencing assays for the examined codons were 97% (K65R), 97% (T69Ins/D), 97% (L74VI), 97% (K103N), 96% (V106AM), 97% (Q151M), 97% (Y181C), 97% (M184VI) and 94% (T215YF) in the reverse transcriptase coding region, and 100% (D30N), 100% (M46I), 100% (G48V), 100% (I50V), 100% (I54LS), 99% (V82A), 99% (I84V) and 100% (L90M) in th
Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.
Abstract: Virological response (HIV-1 RNA <50 copies/mL) was assessed according to: screening HIV-1 RNA (>= or <50000 copies/mL), CD4 cell count, prior protease inhibitor (PI) use, number of active NRTIs in the OBR, presence of mutations (primary PI mutations, PI RAMs or M184V/I), gender, age, race, HIV-1 clade and adherence.
Transmitted HIV drug resistance in treatment-naive Romanian patients.
Discussion: An in vivo fitness cost associated with the M184V/I mutation has been previously shown in patients naive to antiretroviral therapy.
High Efficacy of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with Suppressed HIV and Preexisting M184 V/I.
PMID: 23612196
2013
Antimicrobial agents and chemotherapy
Abstract: Each of the E138A/G/K/Q/R mutations, alone or in combination with M184I, resulted in decreased susceptibility to RPV and etravirine (ETR).
Abstract: Impacts of mutations at position E138 (A/G/K/Q/R/V) alone or in combination with M184I in HIV-1 reverse transcriptase (RT) were investigated.
Abstract: The E138K/Q/R mutations can compensate for M184I in regard to both enzymatic fitness and viral replication capacity.
Abstract: The addition of M184I to the E138 mutations did not significantly change the levels of diminution in drug susceptibility.
Abstract: The favored emergence o
Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy--implications for sustained efficacy of ART in resource-limited settings.
PMID: 23687293
2013
The Journal of infectious diseases
Abstract: There was also a significant difference in prevalence of M184V/I between NNRTI and PI (crude unweighted prevalence 3.2% vs 1.4%); difference 1.6% (95% CI 0.1-3.1; P = .0368).
HIV mutation literature information.
PMID: 
2013
The Journal of antimicrobial chemotherapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT